CNIS793E12201 An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic col

NCT04952753

An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer

Associated Conditions

Colorectal Cancer

Principal Investigator

Sponsor

Novartis Pharmaceuticals Corporation

We are inviting you to be in a research study to find out if adding an investigational compound NIS793 by itself or in combination with a compound tislelizumab to standard anti-cancer therapy can potentially improve treatment of metastatic colorectal cancer (mCRC).